Elanco to buy venture-backed Prevtec Microbia for $78.5 mln
Prevtec Microbia Inc, a Montréal-based biotechnology company focused on the prevention of diseases in food animals, has agreed to be acquired by Elanco Animal Health Inc (NYSE: ELAN). Elanco, a Greenfield, Indiana-based animal health company, agreed to pay $78.5 million in cash. The deal also includes a payment of up to $21.5 million to former shareholders in Q1 2022 if certain sales milestones are met. Founded in 2003, Prevtec is the maker of the Coliprotec line of vaccine products designed to protect pigs against post-weaning diarrhea and associated clinical signs caused by E. coli. Prevtec has been backed in financings by Desjardins-Innovatech, Echo Capital, Investissement Québec, Telesystem, Vet Venture Capital and other investors.
1 August 2019•4 mins read
